A new class of drugs labeled senolytics that may combat some of the factors associated with aging has been identified by researchers at the Scripps Research Institute. Senescent cells are those which have stopped dividing, and their accumulation has been associated with accelerated aging.
In an article published in the August 2015 issue of Aging Cell, Paul Robbins, PhD, and colleagues document their discovery of increased expression of pro-survival networks in senescent cells. Compounds that target these networks, dubbed senolytics, include the drug dasatinib and the nutrient quercetin, which is found in fruits and vegetables, and is also available as a nutritional supplement. While dasatinib was found to reduce senescent human fat cell progenitors, quercetin showed a greater effect against senescent human endothelial cells and mouse bone marrow mesenchymal stem cells. The combination of both compounds was shown to eliminate senescent mouse embryonic fibroblasts.
"We view this study as a big, first step toward developing treatments that can be given safely to patients to extend healthspan or to treat age-related diseases and disorders," stated Dr Robbins. "When senolytic agents, like the combination we identified, are used clinically, the results could be transformative."
"In animal models, the compounds improved cardiovascular function and exercise endurance, reduced osteoporosis and frailty, and extended healthspan," reported research team member Laura J. Niedernhofer. "Remarkably, in some cases, these drugs did so with only a single course of treatment."
"Senescence is involved in a number of diseases and pathologies so there could be any number of applications for these and similar compounds," Dr Robbins added. "Also, we anticipate that treatment with senolytic drugs to clear damaged cells would be infrequent, reducing the chance of side effects."